ABOUT US

With decades of combined experience and a foundation in GSK’s legacy, our team delivers innovative solutions across vaccines and biologics.

ABOUT BIODEXTRIS

Built on the legacy of GSK and powered by a state-of-the-art GMP facility, Biodextris is a dedicated biologics CDMO partner for innovators throughout their product journey.


We provide end-to-end services from preclinical to clinical development, offering the agility, reliability, and flexibility needed to bring new therapies to patients. By combining proven expertise with cutting-edge infrastructure, Biodextris helps biopharma partners scale with confidence — from the earliest stages of innovation to delivering life-changing medicines worldwide. We provide expertise in:

  • Analytical Development & Qualification
  • QC Release & Stability Testing
  • Process Development
  • GMP Biomanufacturing

At Biodextris, we pride ourselves on being a 5F CDMO —

Focused-on-Patients, Friendly, Fast, Flexible, and Future-Driven — delivering reliable results with a human touch and a clear eye on innovation.

Focused-on-Patients

Reliability That Saves Lives
Your success is our mission. We deliver with the integrity and consistency patients depend on.

Friendly

Human-Centered Partnership
We speak your language — approachable, collaborative, and aligned with your goals.

Flexible

Built for Complexity
From custom solutions to evolving needs, we adapt to science as it unfolds.

Fast

Speed With Precision
Rapid timelines without compromising quality — because we know time matters.

Future-Driven

Scalable Innovation
Designed for what’s next, we build with commercial thinking from the start to meet scale and cost.

OUR STORY

1999

Intellivax established for adjuvant development

2002

Acquired by ID Biomedical for vaccine development

2004

IDB acquires Shire
influenza division

2005

Acquired by GSK for vaccine
development and production

2015

Biodextris become an
independant vaccines
& biologics CDMO

2021

Acquired by Archimed, a healthcare-focused investment fund.

OUR MANAGEMENT TEAM

OUR BOARD MEMBERS

Biodextris’ Vision and Positioning from our Chairman

In today’s biopharma world, new modalities, complex pipelines, and tight timelines demand more from CDMOs. At Biodextris, we see our mission as serving innovators, not just as a service provider, but as a true partner in advancing breakthrough therapies.

That is why our vision is built on the 5F Norms. We are Focused on patients, delivering quality they can trust. We are Friendly, fostering real collaboration with our clients. We are Flexible, offering solutions for every challenge. We are Fast, moving with speed and precision because time matters. And we are Future-driven, creating scalable and innovative solutions for tomorrow.

This is the spirit of Biodextris, to stand beside innovators with integrity, agility, and purpose, helping transform bold science into medicines that change lives.

OUR FACILITY

In 2024, the whole team of Biodextris move to this new state of the art facility

32,000 sq. ft (3,000 m²) of custom-designed
CDMO facility

8,000 sq. ft (750 m²) of process development,
analytical & QC labs

6,500 sq. ft (600 m²) of GMP biomanufacturing
cleanrooms

2,500 sq. ft (230 m²) of controlled material
warehousing

GET IN TOUCH WITH OUR FRIENDLY TEAM

Please feel welcome to contact our friendly reception staff with any enquiry. We will answer to you shortly!

Contact - Contact Us